GT Biopharma, Inc. (GTBP)
NASDAQ: GTBP · Real-Time Price · USD
0.417
-0.052 (-11.14%)
At close: Mar 9, 2026, 4:00 PM EDT
0.437
+0.020 (4.80%)
After-hours: Mar 9, 2026, 7:17 PM EDT
GT Biopharma Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Cash & Equivalents | 6.81 | 3.95 | 1.08 | 5.67 | 8.97 | Upgrade
|
| Short-Term Investments | - | - | 12.89 | 10.84 | 23.01 | Upgrade
|
| Cash & Short-Term Investments | 6.81 | 3.95 | 13.97 | 16.51 | 31.98 | Upgrade
|
| Cash Growth | 72.39% | -71.72% | -15.36% | -48.38% | 503.72% | Upgrade
|
| Prepaid Expenses | 0.57 | 0.19 | 0.08 | 0.05 | 0.19 | Upgrade
|
| Restricted Cash | 0.09 | 0.09 | - | - | - | Upgrade
|
| Other Current Assets | 0.63 | - | - | - | - | Upgrade
|
| Total Current Assets | 8.11 | 4.23 | 14.06 | 16.56 | 32.17 | Upgrade
|
| Property, Plant & Equipment | - | - | 0.05 | 0.17 | - | Upgrade
|
| Other Long-Term Assets | - | - | - | 0.01 | - | Upgrade
|
| Total Assets | 8.11 | 4.23 | 14.11 | 16.74 | 32.17 | Upgrade
|
| Accounts Payable | 0.75 | 3.85 | 4.33 | 3.14 | 8.19 | Upgrade
|
| Accrued Expenses | 1.56 | 1.8 | 1.2 | 1.67 | 1.9 | Upgrade
|
| Short-Term Debt | - | - | - | - | 0.03 | Upgrade
|
| Current Portion of Leases | - | - | 0.06 | 0.11 | - | Upgrade
|
| Other Current Liabilities | 0.01 | 0.25 | 1.05 | 0.02 | 0.14 | Upgrade
|
| Total Current Liabilities | 2.32 | 5.9 | 6.63 | 4.94 | 10.26 | Upgrade
|
| Long-Term Leases | - | - | - | 0.06 | - | Upgrade
|
| Total Liabilities | 2.32 | 5.9 | 6.63 | 5 | 10.26 | Upgrade
|
| Common Stock | 0.03 | 0 | 0 | 0.03 | 0.03 | Upgrade
|
| Additional Paid-In Capital | 729.66 | 693.55 | 689.54 | 686.17 | 674.35 | Upgrade
|
| Retained Earnings | -723.9 | -695.23 | -682.07 | -674.47 | -653.58 | Upgrade
|
| Comprehensive Income & Other | - | - | - | - | 1.11 | Upgrade
|
| Total Common Equity | 5.79 | -1.67 | 7.48 | 11.73 | 21.91 | Upgrade
|
| Shareholders' Equity | 5.79 | -1.67 | 7.48 | 11.73 | 21.91 | Upgrade
|
| Total Liabilities & Equity | 8.11 | 4.23 | 14.11 | 16.74 | 32.17 | Upgrade
|
| Total Debt | - | - | 0.06 | 0.17 | 0.03 | Upgrade
|
| Net Cash (Debt) | 6.81 | 3.95 | 13.91 | 16.33 | 31.95 | Upgrade
|
| Net Cash Growth | 72.39% | -71.60% | -14.82% | -48.87% | - | Upgrade
|
| Net Cash Per Share | 1.24 | 2.08 | 10.32 | 15.38 | 34.04 | Upgrade
|
| Filing Date Shares Outstanding | 31.55 | 2.23 | 1.38 | 1.23 | 1.07 | Upgrade
|
| Total Common Shares Outstanding | 25.53 | 2.23 | 1.38 | 1.09 | 1.07 | Upgrade
|
| Working Capital | 5.79 | -1.67 | 7.42 | 11.62 | 21.91 | Upgrade
|
| Book Value Per Share | 0.23 | -0.75 | 5.41 | 10.76 | 20.50 | Upgrade
|
| Tangible Book Value | 5.79 | -1.67 | 7.48 | 11.73 | 21.91 | Upgrade
|
| Tangible Book Value Per Share | 0.23 | -0.75 | 5.41 | 10.76 | 20.50 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.